We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Genetic Testing Unravels Unusual Patterns for Fragile-X Syndrome

By LabMedica International staff writers
Posted on 11 Dec 2017
Fragile-X syndrome is an X-linked disorder with a prevalence of about 1 in 3,600 to 4,000 in males and 1 in 4,000 to 6,000 in females and is the main cause of inherited intellectual disability (ID) and cognitive impairment.

Fragile-X syndrome (FXS) is a rare disease and ID is frequently associated with chromosomal imbalances that often involve the X chromosome, and most clinicians primarily request molecular diagnosis of FXS for patients affected by any type of ID or developmental delay.

Scientists at the University of Naples Federico II (Naples, Italy) and their colleagues studied three women affected by intellectual/psychomotor delay and primary or secondary amenorrhea, and six men affected by mental retardation or psychomotor delay. More...
The enrollees underwent FXS molecular diagnosis and resulted to have normal CGG triplets in the Fragile X Mental Retardation 1 (FMR1) gene, but showed atypical X chromosome patterns. Further diagnostic investigations and, in two females, array-comparative genomic hybridization (array-CGH) revealed the possible genetic cause of their conditions.

The team extracted DNA from 10 mL of whole blood samples from each subject and the CGG repeat number of FMR1 alleles up to 160 CGG repeats was determined by capillary gel electrophoresis of fluorescent-labeled DNA amplicons using primers F (labeled with NED fluorochrome) and C. The triplet repeat primed polymerase chain reaction (TP-PCR) and the Southern blot analysis of genomic DNA digested with restriction enzymes were performed. The X-inactivation analysis was carried out with the PCR-based method for methylation-dependent amplification of the polymorphic triplet repeats at the human androgen receptor (HUMARA) gene. Amplification products were separated by capillary gel electrophoresis on the ABI Prism 3130 genetic analyzer.

The investigators reported that six men affected by ID and three women affected by ID and fragile X-associated premature ovarian failure/ primary ovarian insufficiency (POF/POI) underwent FXS molecular testing. They had normal FMR1 CGG repeats, but atypical X chromosome patterns. Further investigations revealed that the six males had Klinefelter syndrome (XXY), one female was a Turner mosaic (X0/XX) and two women had novel rearrangements involving X chromosome.

The authors concluded that diagnostic investigation of atypical patterns at FMR1 locus can address patients and/or their relatives to further verify the condition by performing karyotyping and/or array-CGH. They emphasize that, for all the presented patients, their diagnostic report concluded for the absence of pathological expansion in the FMR1 gene and the presence of analytical findings that were suggestive of X chromosome abnormality. The study was published online on November 21, 2017, in the journal Clinica Chimica Acta.

Related Links:
University of Naples Federico II


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Giardia Assay
AccuDiag Giardia
New
Whole Blood Control
Lyphochek Whole Blood Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Mimix Reference Standards are cell-line derived to maintain genomic complexity and mimic patient material across molecular diagnostics workflows (Photo courtesy of Revvity)

New Cancer Testing Standards to Improve Diagnostic Accuracy for Oncology Labs

Accurate diagnosis, including the identification of genomic markers, is essential for determining the most effective cancer treatments for patients. To ensure this, laboratories require reliable reference... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.